Consensus on the exercise and dosage variables of an exercise training programme for chronic non-specific neck pain: protocol for an international e-Delphi study.

Clinical guidelines and systematic reviews recommend exercise in the management of chronic non-specific neck pain. Although exercise training programmes that consist of both motor control exercise and exercises for the superficial cervical muscles (segmental exercises) are effective, the exercise variables including dosage vary considerably across trials or are poorly reported.

This study aims to gain expert consensus on these exercise variables so that they can be described clearly using intervention reporting checklists to inform clinical practice and future clinical trials.This protocol for an international Delphi study is informed by the Guidance on Conducting and REporting DElphi Studies recommendations and published to ensure quality, rigour and transparency.

The study will consist of three rounds using anonymous online questionnaires. Expert exercise professionals (physiotherapists, strength and conditioning coaches and so on) and academics in neck pain management will be identified through literature searches, peer referral and social media calls for expression of interest. In round 1, participants will answer open-ended questions informed by intervention and exercise reporting checklists. Responses will be analysed thematically by two independent reviewers.

In round 2, participants will rate their level of agreement with statements generated from round 1 and previous clinical trials using a 5-point Likert scale where 1=strongly disagree and 5=strongly agree. In round 3, participants will re-rate their agreement with statements that achieved consensus in round 2. Statements reaching consensus among participants must meet progressively increased a priori criteria at rounds 2 and 3, measured using descriptive statistics: median, IQR and percentage agreement.

Human NOP58 Ribonucleoprotein (NOP58) ELISA Kit
abx381850-96tests	Abbexa	96 tests	1093.2 EUR
NOP58 Antibody
DF13192	Affbiotech	200ul	420 EUR
NOP58 siRNA
20-abx926153	Abbexa	661.20 EUR 878.40 EUR	15 nmol 30 nmol
NOP58 siRNA
20-abx926154	Abbexa	661.20 EUR 878.40 EUR	15 nmol 30 nmol
NOP58 Antibody
1-CSB-PA896703LA01HU	Cusabio	380.40 EUR 402.00 EUR	100ug 50ug
Description: A polyclonal antibody against NOP58. Recognizes NOP58 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:500-1:5000, IF:1:50-1:200
NOP58 Antibody
1-CSB-PA015940GA01HU	Cusabio	716.40 EUR 399.60 EUR	150ul 50ul
Description: A polyclonal antibody against NOP58. Recognizes NOP58 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB
NOP58 antibody
70R-18924	Fitzgerald	50 ul	522 EUR
Description: Rabbit polyclonal NOP58 antibody
NOP58 siRNA
20-abx903599	Abbexa	661.20 EUR 878.40 EUR	15 nmol 30 nmol
NOP58 Blocking Peptide
DF13192-BP	Affbiotech	1mg	234 EUR
anti- NOP58 antibody
FNab05796	FN Test	100µg	606.3 EUR
Description: Antibody raised against NOP58
NOP5/NOP58 antibody
70R-3412	Fitzgerald	50 ug	560.4 EUR
Description: Rabbit polyclonal NOP5/NOP58 antibody raised against the middle region of NOP5/NOP58
NOP58 Rabbit pAb
A14129-100ul	Abclonal	100 ul	369.6 EUR
NOP58 Rabbit pAb
A14129-200ul	Abclonal	200 ul	550.8 EUR
NOP58 Rabbit pAb
A14129-20ul	Abclonal	20 ul	219.6 EUR
NOP58 Rabbit pAb
A14129-50ul	Abclonal	50 ul	267.6 EUR
NOP58 Polyclonal Antibody
30604-100ul	SAB	100ul	302.4 EUR
NOP58 Polyclonal Antibody
30604-50ul	SAB	50ul	224.4 EUR
NOP58 Polyclonal Antibody
28438-100ul	SAB	100ul	302.4 EUR
NOP58 Polyclonal Antibody
28438-50ul	SAB	50ul	224.4 EUR
NOP58 Rabbit pAb
A4749-100ul	Abclonal	100 ul	369.6 EUR
NOP58 Rabbit pAb
A4749-200ul	Abclonal	200 ul	550.8 EUR
NOP58 Rabbit pAb
A4749-20ul	Abclonal	20 ul	219.6 EUR
NOP58 Rabbit pAb
A4749-50ul	Abclonal	50 ul	267.6 EUR
NOP58 Polyclonal Antibody
A54768	EpiGentek	100 µg	684.66 EUR
Description: kits suitable for this type of research
Anti-NOP58 antibody
PAab05796	Lifescience Market	100 ug	426 EUR
pDONR223-NOP58 Plasmid
PVTB01144-1	Lifescience Market	2 ug	427.2 EUR
Anti-NOP58 antibody
STJ24780	St John's Laboratory	100 µl	332.4 EUR
Description: The protein encoded by this gene is a core component of box C/D small nucleolar ribonucleoproteins. Some box C/D small nucleolar RNAs (snoRNAs), such as U3, U8, and U14, are dependent upon the encoded protein for their synthesis. This protein is SUMOylated, which is necessary for high affinity binding to snoRNAs.
Anti-NOP58 antibody
STJ116064	St John's Laboratory	100 µl	332.4 EUR
Description: The protein encoded by this gene is a core component of box C/D small nucleolar ribonucleoproteins. Some box C/D small nucleolar RNAs (snoRNAs), such as U3, U8, and U14, are dependent upon the encoded protein for their synthesis. This protein is SUMOylated, which is necessary for high affinity binding to snoRNAs.
NOP58 Polyclonal Conjugated Antibody
C30604	SAB	100ul	476.4 EUR
Rat NOP58 shRNA Plasmid
20-abx986026	Abbexa	961.20 EUR 1345.20 EUR	150 µg 300 µg
NOP58 Polyclonal Conjugated Antibody
C28438	SAB	100ul	476.4 EUR
Human NOP58 shRNA Plasmid
20-abx959853	Abbexa	961.20 EUR 1345.20 EUR	150 µg 300 µg
Mouse NOP58 shRNA Plasmid
20-abx974581	Abbexa	961.20 EUR 1345.20 EUR	150 µg 300 µg
NOP58 Antibody, HRP conjugated
1-CSB-PA896703LB01HU	Cusabio	380.40 EUR 402.00 EUR	100ug 50ug
Description: A polyclonal antibody against NOP58. Recognizes NOP58 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
NOP58 Antibody, FITC conjugated
1-CSB-PA896703LC01HU	Cusabio	380.40 EUR 402.00 EUR	100ug 50ug
Description: A polyclonal antibody against NOP58. Recognizes NOP58 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
NOP58 Antibody, Biotin conjugated
1-CSB-PA896703LD01HU	Cusabio	380.40 EUR 402.00 EUR	100ug 50ug
Description: A polyclonal antibody against NOP58. Recognizes NOP58 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
NOP5/NOP58 Blocking Peptide
33R-5398	Fitzgerald	100 ug	216 EUR
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of NOP5/NOP58 antibody, catalog no. 70R-3412
NOP58 ELISA KIT|Human
EF001287	Lifescience Market	96 Tests	826.8 EUR
NOP58 Recombinant Protein (Human)
RP021472	ABM	100 ug	Ask for price
NOP58 Recombinant Protein (Rat)
RP214229	ABM	100 ug	Ask for price
NOP58 Recombinant Protein (Mouse)
RP154577	ABM	100 ug	Ask for price
Human Nucleolar protein 58 (NOP58)
1-CSB-EP896703HU	Cusabio	456.00 EUR 256.80 EUR 1570.80 EUR 672.00 EUR 1047.60 EUR 314.40 EUR	100ug 10ug 1MG 200ug 500ug 50ug
Description: Recombinant Human Nucleolar protein 58(NOP58) expressed in E.coli
NOP58 Polyclonal Antibody, Biotin Conjugated
A54765	EpiGentek	100 µg	684.66 EUR
Description: The best epigenetics products
NOP58 Polyclonal Antibody, FITC Conjugated
A54766	EpiGentek	100 µg	684.66 EUR
Description: kits suitable for this type of research
NOP58 Polyclonal Antibody, HRP Conjugated
A54767	EpiGentek	100 µg	684.66 EUR
Description: fast delivery possible
Nop58 ORF Vector (Rat) (pORF)
ORF071411	ABM	1.0 ug DNA	607.2 EUR
NOP58 ORF Vector (Human) (pORF)
ORF007158	ABM	1.0 ug DNA	114 EUR
Nop58 ORF Vector (Mouse) (pORF)
ORF051527	ABM	1.0 ug DNA	607.2 EUR
NOP58 sgRNA CRISPR Lentivector set (Human)
K1441001	ABM	3 x 1.0 ug	406.8 EUR
Nop58 sgRNA CRISPR Lentivector set (Mouse)
K4828601	ABM	3 x 1.0 ug	406.8 EUR
Nop58 sgRNA CRISPR Lentivector set (Rat)
K6841801	ABM	3 x 1.0 ug	406.8 EUR
Human Nucleolar protein 58, NOP58 ELISA KIT
ELI-38275h	Lifescience Market	96 Tests	988.8 EUR
Mouse Nucleolar protein 58, Nop58 ELISA KIT
ELI-38276m	Lifescience Market	96 Tests	1038 EUR
NOP58 sgRNA CRISPR Lentivector (Human) (Target 1)
K1441002	ABM	1.0 ug DNA	184.8 EUR
NOP58 sgRNA CRISPR Lentivector (Human) (Target 2)
K1441003	ABM	1.0 ug DNA	184.8 EUR
NOP58 sgRNA CRISPR Lentivector (Human) (Target 3)
K1441004	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Mouse) (Target 1)
K4828602	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Mouse) (Target 2)
K4828603	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Mouse) (Target 3)
K4828604	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Rat) (Target 1)
K6841802	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Rat) (Target 2)
K6841803	ABM	1.0 ug DNA	184.8 EUR
Nop58 sgRNA CRISPR Lentivector (Rat) (Target 3)
K6841804	ABM	1.0 ug DNA	184.8 EUR
NOP58 Protein Vector (Human) (pPB-C-His)
PV028629	ABM	500 ng	394.8 EUR
NOP58 Protein Vector (Human) (pPB-N-His)
PV028630	ABM	500 ng	394.8 EUR
NOP58 Protein Vector (Human) (pPM-C-HA)
PV028631	ABM	500 ng	394.8 EUR
NOP58 Protein Vector (Human) (pPM-C-His)
PV028632	ABM	500 ng	394.8 EUR
Human Nucleolar protein 58(NOP58)ELISA Kit
QY-E03190	Qayee Biotechnology	96T	472.8 EUR
NOP58 Protein Vector (Rat) (pPB-C-His)
PV285642	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Rat) (pPB-N-His)
PV285643	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Rat) (pPM-C-HA)
PV285644	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Rat) (pPM-C-His)
PV285645	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Mouse) (pPB-C-His)
PV206106	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Mouse) (pPB-N-His)
PV206107	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Mouse) (pPM-C-HA)
PV206108	ABM	500 ng	723.6 EUR
NOP58 Protein Vector (Mouse) (pPM-C-His)
PV206109	ABM	500 ng	723.6 EUR
Nop58 3'UTR Luciferase Stable Cell Line
TU214085	ABM	1.0 ml	Ask for price
Nop58 3'UTR GFP Stable Cell Line
TU264085	ABM	1.0 ml	Ask for price
NOP58 3'UTR Luciferase Stable Cell Line
TU015825	ABM	1.0 ml	1825.2 EUR
Nop58 3'UTR Luciferase Stable Cell Line
TU114212	ABM	1.0 ml	Ask for price
Nop58 3'UTR GFP Stable Cell Line
TU164212	ABM	1.0 ml	Ask for price
NOP58 3'UTR GFP Stable Cell Line
TU065825	ABM	1.0 ml	1825.2 EUR
NOP58 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
LV692263	ABM	1.0 ug DNA	818.4 EUR
NOP58 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)
LV692267	ABM	1.0 ug DNA	818.4 EUR
NOP58 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)
LV692268	ABM	1.0 ug DNA	818.4 EUR
Recombinant Candida Albicans NOP58 Protein (aa 1-516)
VAng-Lsx05762-inquire	Creative Biolabs	inquire	Ask for price
Description: Candida Albicans (strain SC5314 / ATCC MYA-2876) Nucleolar protein 58, recombinant protein.
NOP58 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
K1441005	ABM	3 x 1.0 ug	451.2 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
K4828605	ABM	3 x 1.0 ug	451.2 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)
K6841805	ABM	3 x 1.0 ug	451.2 EUR
NOP58 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV692264	ABM	1.0 ug DNA	818.4 EUR
NOP58 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV692265	ABM	1.0 ug DNA	888 EUR
NOP58 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV692266	ABM	1.0 ug DNA	888 EUR
NOP58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
K1441006	ABM	1.0 ug DNA	200.4 EUR
NOP58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
K1441007	ABM	1.0 ug DNA	200.4 EUR
NOP58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
K1441008	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
K4828606	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
K4828607	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)
K4828608	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)
K6841806	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)
K6841807	ABM	1.0 ug DNA	200.4 EUR
Nop58 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)
K6841808	ABM	1.0 ug DNA	200.4 EUR

Inferential statistics will be used to evaluate measures of agreement between participants (Kendall’s coefficient of concordance) and stability between rounds (Wilcoxon rank-sum test). Statements achieving consensus in round 3 will provide expert recommendations of the key exercise and dosage variables in the management of chronic non-specific neck pain.Ethical approval was provided by the University of Birmingham Ethics Committee (Ref:ERN_19-1857). Results will be disseminated through peer-reviewed publications and conference presentations.